01 / 74 · 0:52 · Original AXON film
KPV
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
KPV | Gut signalling
How does a three-amino-acid peptide get inside a gut cell? That question sits at the centre of KPV research. [1]
CELL STUDY | PepT1 transport
In laboratory-grown intestinal and immune cells, researchers found that a transporter called PepT1 could carry KPV inside. Inflammatory signalling then changed. [1]
MOUSE MODELS | Patient benefit unproven
The same research reported reduced inflammation in mouse models of colitis. Human-derived cells and mice are useful steps, but neither establishes treatment benefits in patients. [1]
RESEARCH STAGE | No treatment claim
FDA reports a lack of human exposure information for KPV drug products. Delivery, safety and meaningful clinical outcomes remain questions to answer before making gut-healing claims. [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation →Primary study; human cell lines and mouse colitis models
- FDA: Certain bulk drug substances that may present significant safety risks →US regulator; route-specific safety assessment, not a universal ban or approval list
